ResMed Inc (RMD)

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Symbol
RMD
Exchange
NYSE
Sector
Healthcare
Industry
Medical Instruments & Supplies
Market cap
$31.57B
52 week range
180.27 - 284.87

Valuation

Share price
$218.89 (close of 2026-10-02)
P/E (TTM)
20.91x
Price to book
4.79x
Price to free cash flow
19.14x
Enterprise value
$30.93B
Book value per share
$45.66

Price performance

PeriodChange
1 day-1.02%
5 days-1.40%
1 month-5.19%
3 months+4.42%
6 months-2.32%
Year to date-9.13%
1 year-20.88%
3 years+50.18%
5 years-16.52%
10 years+237.85%
All time+32570.15%

Members of Congress who disclosed RMD trades

Kelly Morrison · Alan Armstrong · Robert Bresnahan · Tommy Tuberville

Super investors holding RMD

Ken Griffin (Citadel) · Francois Rochon (Giverny Capital Inc) · Ray Dalio (Bridgewater Associates)

Profitability and growth

Return on equity
23.13%
Return on invested capital
25.09%
Return on assets
16.99%
Return on capital employed
24.92%
Gross margin
61.06%
Net margin
26.94%
EBITDA margin
36.93%
Revenue growth
9.85%
Net income growth
8.75%
Free cash flow growth
-0.73%

Cash flow and balance sheet

Free cash flow yield (TTM)
5.22%
Current ratio
3.10x
Net debt to EBITDA
-0.30x

Latest reported year

Period end
2026-06-30
Fiscal year
2026
Revenue
$5.65B
Cost of revenue
$2.20B
Gross profit
$3.45B
EBITDA
$2.09B
Net income
$1.52B
Earnings per share
$10.47
Research and development
$378.29M
Shares outstanding
145.52M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2026-06-30$5.65B$3.45B$1.52B$10.47
2025-06-30$5.15B$3.05B$1.40B$9.55
2024-06-30$4.69B$2.66B$1.02B$6.94
2023-06-30$4.22B$2.36B$897.56M$6.12
2022-06-30$3.58B$2.02B$779.44M$5.34
2021-06-30$3.20B$1.84B$474.50M$3.27
2020-06-30$2.96B$1.72B$621.67M$4.31
2019-06-30$2.61B$1.49B$404.59M$2.83
2018-06-30$2.34B$1.33B$315.59M$2.21
2017-06-30$2.07B$1.20B$342.28M$2.42

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2026-06-3061.06%26.94%23.13%25.09%
2025-06-3059.36%27.22%23.47%25.11%
2024-06-3056.67%21.79%20.99%19.57%
2023-06-3055.78%21.25%21.73%16.92%
2022-06-3056.57%21.78%23.19%20.46%
2021-06-3057.53%14.84%16.44%14.61%
2020-06-3058.09%21.02%24.90%20.95%
2019-06-3057.32%15.52%19.52%14.55%
2018-06-3057.04%13.49%15.33%15.62%
2017-06-3058.15%16.56%17.46%15.76%

Cash and debt by year

Period endCashDebt
2026-06-30$1.47B$399.42M
2025-06-30$1.21B$658.39M
2024-06-30$238.36M$697.31M
2023-06-30$227.89M$1.43B
2022-06-30$273.71M$765.33M
2021-06-30$295.28M$643.35M
2020-06-30$463.16M$1.16B
2019-06-30$147.13M$1.26B
2018-06-30$188.70M$269.99M
2017-06-30$821.93M$1.08B

Free cash flow by year

Period endFree cash flowStock-based compensation
2026-06-30$1.65B$104.35M
2025-06-30$1.66B$91.66M
2024-06-30$1.30B$80.18M
2023-06-30$573.63M$71.14M
2022-06-30$216.31M$65.26M
2021-06-30$634.01M$63.93M
2020-06-30$706.92M$57.56M
2019-06-30$390.34M$52.07M
2018-06-30$442.44M$48.41M
2017-06-30$351.83M$45.92M

Dividend history

Most recent payment
2026-08-20
Paid in the last twelve months
$2.46
Payment dateDividend per share
2026-08-20$0.66
2026-05-14$0.60
2026-02-12$0.60
2025-11-13$0.60
2025-08-14$0.60
2025-05-08$0.53
2025-02-13$0.53
2024-11-07$0.53

Investor relations

Next earnings report

Next confirmed report
2026-10-29
Consensus EPS estimate
$2.70

Past earnings dates

ReportedFiscal periodEPS estimate
2026-08-06Jun/2026$2.90
2026-04-30Mar/2026$2.79
2026-01-29Dec/2025$2.69
2025-10-30Sep/2025$2.49
2025-07-31Jun/2025$2.46
2025-04-23Mar/2025$2.36
2025-01-30Dec/2024$2.30
2024-10-24Sep/2024$2.03

Filings and sources

Company website
resmed.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Alcon Inc (ALC) · Becton Dickinson & Co (BDX) · Medline Inc. (MDLN) · Intuitive Surgical Inc (ISRG) · West Pharmaceutical Services Inc (WST) · Solventum Corp (SOLV) · Henry Schein Inc (HSIC) · Cardinal Health Inc (CAH)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades